Table 1 Baseline characteristics of the included studies
Fist author (year) | Country | Sample size (n) | BMSC group (n) | CABG group (n) | Follow-up (months) | Age (years) | Sex, (male/female) | Type of stem cells | Dose of stem cells | Route of cell administration | Treatment of control group | Method for determining outcome measure | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BMSC Group | CABG Group | BMSC Group | CABG Group | |||||||||||
Patel et al. (2005) | Argentina | 20 | 10 | 10 | 6 | 64.8 ± 3.9 | 63.6 ± 4.9 | 8/2 | 8/2 | CD 34 + | 22.0 × 10^6(median) | IM | off-pump CABG-only | ECHO |
Hendrikx et al. (2006) | Belgium | 20 | 10 | 10 | 4 | 63.2 ± 8.5 | 66.8 ± 9.2 | 10/0 | 7/3 | BMC | 60.25 ± 31.35 × 10^6 | IM | CABG-only | MRI |
Stamm et al. (2007) | Germany | 40 | 20 | 20 | 12 | 62 ± 10.2 | 63.5 ± 8.4 | 15/5 | 16/4 | CD 133 + | 5.80 ± 10^6(median)(range 1.08 × 10^6 to 8.35 × 10^7) | IM | CABG-only | ECHO |
Ang et al. (2008) | UK | 62 | 21/21a | 20 | 6 | 64.7 ± 8.7/62.1 ± 8.7 | 61.3 ± 8.3 | 15/6,19/2 | 18/2 | BMC | 84 ± 56 × 10^6/115 ± 73 × 10^6 | IM/IC | CABG-only | MRI |
Zhao et al. (2008) | China | 36 | 18 | 18 | 6 | 60.3 ± 10.4 | 59.1 ± 15.7 | 15/3 | 15/3 | BMMNC | 6.59 ± 5.12 × 10^8 | IM | CABG + placebo | ECHO |
Hu et al. (2011) | China | 60 | 31 | 29 | 6 | 56.61 ± 9.72 | 58.27 ± 8.86 | NA | NA | BMMNC | 13.17 ± 10.66 × 10^7 | IC | CABG + placebo | MRI |
Maureira et al. (2012) | France | 14 | 7 | 7 | 6 | 58 ± 10 | 57 ± 10 | 7/0 | 6/1 | BMMNC | NA | IM | CABG only | MRI |
Lu et al. (2013) | China | 50 | 25 | 25 | 12 | 58.0 ± 7.8 | 57.0 ± 8.3 | 22/3 | 24/1 | BMMNC | 13.38 ± 8.14 × 10^7 | IC | CABG + placebo | MRI |
Nasseri et al. (2014) | Germany | 60 | 30 | 30 | 6 | 61.9 ± 7.3 | 62.7 ± 10.6 | 28/2 | 29/1 | CD 133 + | 5.1 ± 1.017 × 10^6(median)(IQR 3.0 × 10^6 to 9.1 × 10^6) | IM | CABG + placebo | MRI |
Pätilä et al. (2014) | Finland | 39 | 20 | 19 | 12 | 65(57–73)(median) | 64(58–70)(median) | 19/1 | 18/1 | BMMNC | 8.4 × 10^8(median)(IQR 5.2 × 10^8 to 13.5 × 10^8) | IM | CABG + placebo | MRI |
Trifunović et al. (2015) | Serbia | 30 | 15 | 15 | 60(median) | 53.8 ± 10.1 | 60 ± 6.8 | 14/1 | 14/1 | BMMNC | 70.7 ± 32.4 × 10^6 | IM | CABG-only | ECHO |
Wang et al. (2015) | China | 90 | 45 | 45 | 6 | 61.4 ± 7.45 | 62.9 ± 6.93 | 37/8 | 35/10 | BMC | 5.21 ± 0.44 × 10^8 | IM | CABG + placebo | ECHO |
Noiseux et al. (2016) | Canada | 33 | 19 | 14 | 6 | 66.4 ± 6.5 | 63.1 ± 7.2 | 17/2 | 13/1 | CD 133 + | 6.5 ± 3.1 × 10^6 | IM | CABG + placebo | MRI |
Wang et al. (2016) | China | 33 | 17 | 16 | 24 | 65.6 ± 3.97 | 65.5 ± 5.6 | NA | NA | BMMNC | 98.5 ± 48.3 × 10^6 | IM | CABG-only | ECHO |
Lu et al. (2017) | China | 40 | 20 | 20 | 24 | 51.7 ± 2.5 | 52.6 ± 3.8 | 8/12 | 12/8 | CD 34 + | NA | IM | CABG-only | ECHO |
Steinhoff et al. (2017) | Germany | 58 | 28 | 30 | 6 | 64.0 ± 7.20 | 63.6 ± 7.75 | 26/2 | 26/4 | CD 133 + | 2.29 ± 1.42 × 10^6 | IM | CABG + placebo | MRI |
Laguna et al. (2018) | Spain | 17 | 8 | 9 | 9 | 62.63 ± 8.35 | 64.78 ± 11.48 | 7/1 | 8/1 | BMMNC | NA | IM | CABG + placebo | ECHO |
Naseri et al. (2018) | Iran | 77 | 21/30b | 26 | 18 | 53.14 ± 8.56/51.45 ± 7.49 | 55.50 ± 8.54 | 19/2,27/3 | 23/3 | MNC/CD 133 + | 8.19 ± 4.26 × 10^6/564.63 ± 69.35 × 10^6 | IM | CABG + placebo | SPECT |
Qi et al. (2018) | China | 42 | 24 | 18 | 12 | 57.88 ± 8.52 | 56.56 ± 9.09 | 23/1 | 17/1 | BMMNC | 13.28 ± 9.41 × 10^7 | IC | CABG + placebo | MRI |
Mann et al. (2019) | Netherlands | 39 | 19 | 20 | 12 | 65 ± 7 | 65 ± 8 | 19/0 | 18/2 | BMMNC | 100 × 10^6 | IM | CABG + placebo | SPECT |
Soetisna et al. (2020) | Indonesia | 26 | 13 | 13 | 6 | 54.61 ± 8.07 | 57.46 ± 6.33 | 12/1 | 12/1 | CD133 + | NA | IM | CABG-only | MRI |
Ulus et al. (2020) | Turkey | 28 | 12 | 16 | 12 | 56.9 ± 1.5(SE) | 65.3 ± 1.7(SE) | 12/0 | 16/0 | BMMNC | 70 × 10^7 | IM | CABG-only | MRI |